Sean A. Power Sells 10,021 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TG Therapeutics Stock Up 2.8 %

TGTX stock opened at $28.77 on Thursday. The stock has a market cap of $4.48 billion, a P/E ratio of -287.67 and a beta of 2.24. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock’s fifty day simple moving average is $31.37 and its two-hundred day simple moving average is $25.25. TG Therapeutics, Inc. has a 1-year low of $12.84 and a 1-year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 earnings per share. Analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. increased its stake in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in TG Therapeutics during the second quarter valued at $35,000. Blue Trust Inc. grew its holdings in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the period. ORG Wealth Partners LLC purchased a new stake in TG Therapeutics in the third quarter worth $53,000. Finally, Values First Advisors Inc. bought a new stake in shares of TG Therapeutics in the third quarter valued at $58,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TGTX has been the subject of a number of analyst reports. HC Wainwright lifted their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.